The role of propensity score matching (PSM) in statistical analysis of effectiveness in medical research is described in this animation
All webinars
Watch and listen to experts as they discuss developments in the field of Duchenne muscular dystrophy (DMD), as presented across live and virtual platforms
Select from our webinar content below:
|
Clinical insights into topics such as the mutational spectrum and disease continuum of DMD, best practice for obtaining a mutation-specific diagnosis, and the role of treatment in DMD management.
PTC Therapeutics is the Marketing Authorization Holder for deflazacort in the US only. Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The US Prescribing Information for deflazacort is available here. Please refer to your local country guidance for more information.
For medical information, product complaints, or to report an adverse event, please call 1-866-562-4620 or email at usmedinfo@ptcbio.com. You may also report adverse events directly to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
MED-ALL-DFZ-2500002 | March 2025
▼ Ataluren is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC Therapeutics at pharmacovigilance@ptcbio.com.
Registration conditions differ internationally; always consult local prescribing information and/or Summary of Product Characteristics before prescribing any products.
MED-ALL-ATLN-2500006 | September 2025
MED-ALL-DMD-2100151 | June 2025